Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:08 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1113
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Chicago Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Chicago Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 733–744 of 1,113 matching trials with a site at University of Chicago Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
12 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Orange, California • Sacramento, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Recruiting No phase listed Observational

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

NCT03151629
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care
Other
Lead sponsor
Prostate Cancer Clinical Trials Consortium
Other
Eligibility
21 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
48
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Genomic Predictors of Recurrent Pregnancy Loss

NCT05444283
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Recurrent Pregnancy Loss
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
10
States / cities
Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Active, not recruiting Phase 1 Interventional

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

NCT02632708
Site status not listed — check the official record
View directory record Official record
Conditions
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
Interventions
AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Recruiting Not applicable Interventional

Cortical Recording and Stimulating Array Brain-Machine Interface

NCT01894802
Status at this site: Recruiting
View directory record Official record
Conditions
Tetraplegia, Spinal Cord Injury, Brainstem Stroke, Brachial Plexus Injury, Above Elbow Amputation
Interventions
Implantation of CRS Arrays
Device
Lead sponsor
Michael Boninger
Other
Eligibility
22 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Recruiting Not applicable Interventional

Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition

NCT06094478
Status at this site: Recruiting
View directory record Official record
Conditions
Stroke, Acute, Ischemic Stroke, Acute, Hemorrhagic Stroke
Interventions
HI-SPEED Protocol
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
New Haven, Connecticut • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
Status at this site: Recruiting
View directory record Official record
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Not yet recruiting Not applicable Interventional

VR Therapies for IBD

NCT07590518
Site status not listed — check the official record
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn Disease (CD), Anxiety
Interventions
Distraction VR, VR/AI CBT
Device
Lead sponsor
Brennan Spiegel
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

NCT04136002
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
45 Years to 84 Years
Enrollment
44,467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
271
States / cities
Anniston, Alabama • Guntersville, Alabama • Huntsville, Alabama + 217 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Placebo, MRI contrast-enhancing agents
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 2, 2026, 2:08 AM EST
Recruiting Not applicable Interventional

Variable Immobilization Protocol for Arthroplasty of the Carpometacarpal Joint of the Thumb

NCT04828954
Status at this site: Recruiting
View directory record Official record
Conditions
Thumb Osteoarthritis
Interventions
Immobilization for 2-weeks postoperative, Immobilization for 6-weeks postoperative
Other
Lead sponsor
University of Chicago
Other
Eligibility
40 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 2, 2026, 2:08 AM EST

About this University of Chicago Medicine institution page

What this page lists
ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.